Revolutionizing Melanoma Treatment: Immunotherapy and Liquid Biopsy

A team of researchers at the University of Siena has reported promising results from a clinical approach combining liquid biopsy monitoring with immunotherapy for patients diagnosed with melanoma that has spread to the brain. The strategy, detailed in findings presented at a recent oncology conference and supported by ongoing data collection, aims to detect treatment response earlier and adjust therapy dynamically in a cancer type historically associated with poor prognosis and limited therapeutic options.

Melanoma brain metastases occur in approximately 10 to 15 percent of patients with advanced melanoma and are often difficult to treat due to the blood-brain barrier, which limits the penetration of many systemic therapies. While immune checkpoint inhibitors have improved survival in metastatic melanoma their effectiveness in the central nervous system remains variable, and assessing response typically relies on periodic magnetic resonance imaging (MRI), which may not reflect biological changes as quickly as molecular markers.

The Siena-based study integrated serial liquid biopsies — blood tests that analyze circulating tumor DNA (ctDNA) — into the monitoring regimen for patients receiving immunotherapy, specifically anti-PD-1 agents such as pembrolizumab or nivolumab, sometimes combined with anti-CTLA-4 therapy. By tracking changes in ctDNA levels over time, researchers sought to identify molecular indicators of tumor burden and treatment response earlier than conventional imaging could detect.

According to the research team, declines in ctDNA levels following the initiation of immunotherapy correlated with radiographic stabilization or reduction in brain lesion size observed on subsequent MRI scans. Conversely, rising or persistent ctDNA levels were associated with disease progression, even when imaging changes were not yet apparent. This ability to detect molecular progression before radiological confirmation could allow clinicians to consider altering treatment strategies sooner, potentially improving outcomes.

Dr. Lorenzo Pazzagli, lead investigator from the Department of Medical Biotechnology at the University of Siena, explained that the goal of integrating liquid biopsy is not to replace imaging but to complement it with a more frequent, minimally invasive tool capable of reflecting real-time tumor dynamics. “We are moving toward a model where treatment decisions can be informed by both imaging and molecular tracking,” he said in a presentation summarized by Italian health news outlet La Nazione. “Liquid biopsy offers a window into tumor activity that MRI alone may miss, especially in the early phases of response or resistance.”

The approach builds on growing evidence that ctDNA analysis can serve as a reliable biomarker in melanoma. Studies published in journals such as Clinical Cancer Research and Nature Medicine have demonstrated that ctDNA levels reflect tumor burden, harbor actionable mutations, and can predict resistance mechanisms in metastatic melanoma. However, its application in brain metastases has been less explored due to assumptions about limited ctDNA shedding from central nervous system tumors — a notion the Siena data challenges.

Preliminary data from the Siena cohort, which included over 60 patients with histologically confirmed melanoma and at least one measurable brain metastasis, showed that ctDNA was detectable in the bloodstream of a majority of patients at baseline. Changes in specific genetic alterations, including mutations in BRAF, NRAS, and NF1 genes, were tracked longitudinally and aligned with clinical outcomes. Patients who achieved a confirmed radiographic response also demonstrated significant ctDNA clearance, while those with emerging resistance often exhibited new mutations in genes linked to immune evasion or MAPK pathway reactivation.

Researchers caution that the findings are based on an observational cohort and require validation in prospective, controlled trials. Liquid biopsy technology, while increasingly accessible, still faces challenges related to assay sensitivity, standardization across platforms, and the potential influence of clonal hematopoiesis on ctDNA interpretation — particularly in older patient populations. The team emphasized that larger studies are needed to define optimal timing for testing, establish clinically meaningful thresholds for change, and determine how liquid biopsy results should directly guide therapeutic modifications such as switching regimens, adding local therapies like stereotactic radiosurgery, or enrolling in trials of novel immunotherapeutic combinations.

Despite these limitations, the integration of molecular monitoring into the management of melanoma brain metastases represents a step toward precision oncology in a setting where timely intervention is critical. The American Association for Cancer Research notes that early detection of treatment failure can open windows for salvage therapies before neurological decline occurs, potentially preserving quality of life and extending survival.

As immunotherapy continues to evolve, combining systemic agents with localized treatments and refining response assessment through biomarkers like ctDNA may improve the management of central nervous system metastases. The Siena team plans to expand its analysis with longitudinal sampling and correlate ctDNA patterns with immune profiling to better understand the biological underpinnings of response and resistance in the brain microenvironment.